Astellas

Astellas to Plug-in-and-Play to Vibrant South San Francisco Immuno-Oncology R&D Ecosystem with Xyphos Buy

Dec 28, 2019 | Acquisition, Astellas, CAR T cell therapy, Immuno-oncology, M&A

Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. to strengthen its immuno-oncology pipeline. With the acquisition Astellas gains Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as...

Astellas Pours $13M more into Boston Life Science Cluster Now Totaling over $1B to Date

Oct 3, 2019 | Astellas, Biotech Cluster, Boston

Astellas Pharma Inc. announced a nearly $13 million investment into two innovation incubators operated by LabCentral, a premier U.S.-based laboratory facility for next-generation biotech startups. Astellas has infused over $1 billion into the Boston-area life...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Astellas to Plug-in-and-Play to Vibrant South San Francisco Immuno-Oncology R&D Ecosystem with Xyphos Buy

Astellas Pours $13M more into Boston Life Science Cluster Now Totaling over $1B to Date

Pin It on Pinterest